Jean-Philippe Baguet,Olivier Ormezzano,Gilles Barone-Rochette
Jean-Philippe Baguet
Telmisartan, a selective angiotensin II type 1 receptor blocker (ARB), has been investigated in many trials, in particular, in order to assess its antihypertensive effect in various situations and its ability to protect organs susceptible t...
Critical appraisal and pooled analysis of telmisartan alone or in combination with hydrochlorothiazide for achieving blood pressure goals [0.03%]
坎地沙坦或与氢氯噻嗪联用治疗以达到降压目标的关键评估及汇总分析
Satoshi Morimoto,Nobuyuki Takahashi,Tatsuyori Morita et al.
Satoshi Morimoto et al.
Rigid control of blood pressure (BP) is essential to prevent cardiovascular disease. However, only about 40% of hypertensive patients undergoing pharmacological intervention with a single agent achieve their BP goals in contemporary clinica...
Critical appraisal of the differential effects of antihypertensive agents on arterial stiffness [0.03%]
评价降压药物对动脉僵硬度的差异化效应
Francesca Kum,Janaka Karalliedde
Francesca Kum
Increased central arterial stiffness, involving accelerated vascular ageing of the aorta, is a powerful and independent risk factor for early mortality and provides prognostic information above and beyond traditional risk factors for cardio...
Fixed combinations in the pragmatic management of hypertension: focus on aliskiren and hydrochlorothiazide as a single pill [0.03%]
高血压实用疗法中的固定复方：着重于阿利吉仑和氢氯噻嗪单片药
Michel Burnier
Michel Burnier
A majority of hypertensive patients need more than one antihypertensive drug to control their blood pressure. For this reason, most guidelines have introduced the possibility of prescribing fixed-dose combination therapies as first-line tre...
Update on the role of candesartan in the optimal management of hypertension and cardiovascular risk reduction [0.03%]
坎地沙坦在高血压最佳治疗和心血管风险降低方面作用的最新研究进展
Ikechi G Okpechi,Brian L Rayner
Ikechi G Okpechi
Hypertension is the most prevalent cardiovascular disease of adults and is a major risk factor for cardiovascular (CV) and cerebrovascular morbidity and mortality worldwide. Treatment of hypertension leads to reduction of CV morbidity and m...
Gerti Tashko,Robert A Gabbay
Gerti Tashko
Blood pressure (BP) control is a critical part of managing patients with type 2 diabetes. Perhaps it is the single most important aspect of diabetes care, which unlike hyperglycemia and dyslipidemia can reduce both micro- and macrovascular ...
Endothelial function, blood pressure control, and risk modification: impact of irbesartan alone or in combination [0.03%]
内皮功能、血压控制及危险因素的修正：依那普利洛单用或合用的效果
Giuseppe Derosa,Sibilla At Salvadeo
Giuseppe Derosa
Irbesartan, an angiotensin II type 1 receptor antagonist, is approved as monotherapy, or in combination with other drugs, for the treatment of hypertension in many countries worldwide. Data in the literature suggest that irbesartan is effec...
Complementary mechanisms of action and rationale for the fixed combination of perindopril and indapamide in treating hypertension - update on clinical utility [0.03%]
培哚普利叔醇片和吲达帕胺片复方制剂治疗高血压的作用机制及临床应用更新
Vivencio Barrios,Carlos Escobar
Vivencio Barrios
Although reducing blood pressure is the most important approach to reduce cardiovascular outcomes in the hypertensive population, the majority of patients fail to attain the targets. Most patients with hypertension need at least 2 antihyper...
Michel E Safar
Michel E Safar
In hypertensive subjects, cardiovascular risk reduction is critically related to the decrease of systolic blood pressure (SBP). De-stiffening therapy means that, in a controlled therapeutic trial of long duration, a selective reduction of S...
Current concepts in combination therapy for the treatment of hypertension: combined calcium channel blockers and RAAS inhibitors [0.03%]
高血压联合治疗的当前概念：钙拮抗剂与RAAS抑制剂的合用
Alberto F Rubio-Guerra,David Castro-Serna,Cesar I Elizalde Barrera et al.
Alberto F Rubio-Guerra et al.
Recent guidelines for the management of hypertension recommend target blood pressures